Eosinophilic Disorders
Eosinophilic dermatoses are a group of inflammatory skin conditions driven by complex immune responses, in which eosinophils appear and build up abnormally in the skin, the small blood vessels or the peripheral blood. Eosinophils are granulocytes that sit at the heart of type 2 (Th2) immunity. When overactivated, they release cytotoxic granule proteins that damage connective tissue and cause marked dermal swelling and fibrosis. The result is a wide range of clinical findings, from papules, pustules and red plaques to necrosis of small vessels.
At Haute-Derma, managing eosinophilic disorders starts with carefully distinguishing disease confined to the skin from systemic infiltrative disease such as hypereosinophilic syndrome (HES). Treatment is layered, combining control of acute inflammation, steroid-sparing immunosuppression and new-generation targeted biologics that shut down the inflammatory cascade at its source.
Pathogenesis: How Eosinophils Damage Tissue
Eosinophils are made in the bone marrow under the control of Th2 cytokines. Skin damage unfolds in several biological steps:
- Recruitment and activation: IL-5 (the key cytokine for eosinophil maturation and survival), IL-4 and IL-13, together with chemokines such as eotaxin-1 (CCL11) and eotaxin-3 (CCL26), draw eosinophils out of the bloodstream, across the vessel wall and into the dermis.
- Degranulation: Once in the skin, eosinophils release four main cationic granule proteins:
- Major basic protein (MBP): Directly toxic to epidermal cells and triggers histamine release from mast cells.
- Eosinophil cationic protein (ECP): Punches holes in target cell membranes, causing microscopic cell necrosis.
- Eosinophil peroxidase (EPO) and eosinophil-derived neurotoxin (EDN): Generate reactive nitrogen and oxygen species (RNS/ROS) that cause oxidative stress and break down collagen.
- Flame figures: A characteristic histologic sign that forms when MBP and ECP coat degenerated collagen fibers in the dermis, producing a microscopic pattern that resembles flickering flames.
Diagnosis and Clinical Assessment at Haute-Derma
- Blood Tests and Absolute Eosinophil Count (AEC)
- A complete blood count (CBC) gives the absolute eosinophil count (AEC).
- Severity: AEC > 500 cells/µL is mild eosinophilia; AEC > 1,500 cells/µL is marked eosinophilia with a risk of end-organ damage.
- Total IgE, serum ECP and an autoantibody screen.
- Skin Biopsy
- A 4–6 mm punch biopsy is taken from an active lesion, deep enough to include the full deep dermis and subcutis.
- Hematoxylin and eosin (H&E) staining shows how dense the infiltrate is, where eosinophil granules are deposited (around follicles, around vessels or in the fascia) and whether flame figures are present.
- Screening for Systemic Disease and End-Organ Damage: Echocardiography, lung function tests, liver enzymes, kidney function and CT scanning are used to rule out internal organ involvement from hypereosinophilic syndrome (HES).
Our Layered Treatment Approach at Haute-Derma
- Controlling Acute Inflammation (First-Line Therapy)
- Systemic corticosteroids: Oral prednisolone or methylprednisolone (0.5–1.0 mg/kg/day) is the first choice. It rapidly lowers eosinophil numbers and blocks the release of toxic granules.
- Topical corticosteroids or calcineurin inhibitors: Clobetasol propionate or tacrolimus 0.1% for localized, superficial lesions.
- Immunosuppressive and Steroid-Sparing Agents
- Dapsone (50–100 mg/day): Inhibits the migration and adhesion of neutrophils and eosinophils (G6PD deficiency must be checked before starting).
- Methotrexate (10–15 mg/week) or cyclosporine A: For chronic disease, steroid-resistant cases or fascial sclerosis (eosinophilic fasciitis).
- Indomethacin: Highly effective for Ofuji disease (eosinophilic pustular folliculitis).
- New-Generation Biologics and Targeted Therapy
- Mepolizumab (Nucala) / benralizumab (Fasenra): Monoclonal antibodies that bind IL-5 or its receptor IL-5Rα, directly depleting eosinophils and cutting off their production.
- Dupilumab (Dupixent): A monoclonal antibody against the shared IL-4/IL-13 receptor alpha chain, blocking Th2 signaling upstream.
- Imatinib mesylate: A tyrosine kinase inhibitor reserved for patients with HES who carry the FIP1L1-PDGFRA fusion gene.
